Coldact Plus New

Coldact Plus New Uses, Dosage, Side Effects, Food Interaction and all others data.

Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.

Phenylpropanolamine (PPA), a sympathomimetic agent structurally similar to pseudoephedrine, is used to treat nasal congestion. Phenylpropanolamine is found in appetite suppressant formulations and with guaifenesinin in cough-cold formulations. In 2000, the FDA requested that all drug companies discontinue marketing products containing phenylpropanolamine, due to an increased risk of hemorrhagic stroke in women who used phenylpropanolamine.

Trade Name Coldact Plus New
Generic Phenylpropanolamine + Chlorpheniramine / Chlorphenamine + Paracetamol / Acetaminophen
Weight 5mg
Type Suspension
Therapeutic Class
Manufacturer Ranbaxy Laboratories (sun Pharma)
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Coldact Plus New
Coldact Plus New

Uses

Phenylpropanolamine is a sympathomimetic that was previously used in nasal decongestants and weight loss products, but has been withdrawn by the FDA due to safety risks and lack of efficacy.

For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.

Coldact Plus New is also used to associated treatment for these conditions: Allergy-Induced Respiratory Symptoms, Bronchitis, Common Cold, Cough, Nasal Congestion, Rhinorrhoea, Excess mucus or phlegm

How Coldact Plus New works

Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect.

Toxicity

May induce ventricular extrasystoles and short paroxysms of ventricular tachycardia, a sensation of fullness in the head and tingling of the extremities; LD50=1490mg/kg (orally in rat)

Elimination Route

Reduced bioavailability (about 38%) from gastrointestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.

Half Life

2.1 to 3.4 hours.

Innovators Monograph

You find simplified version here Coldact Plus New


*** Taking medicines without doctor's advice can cause long-term problems.
Share